ATE205195T1 - Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren - Google Patents
Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitorenInfo
- Publication number
- ATE205195T1 ATE205195T1 AT98947694T AT98947694T ATE205195T1 AT E205195 T1 ATE205195 T1 AT E205195T1 AT 98947694 T AT98947694 T AT 98947694T AT 98947694 T AT98947694 T AT 98947694T AT E205195 T1 ATE205195 T1 AT E205195T1
- Authority
- AT
- Austria
- Prior art keywords
- formula
- phenyl
- protein transferase
- imidazole derivatives
- transferase inhibitors
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000000686 lactone group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97402505 | 1997-10-22 | ||
| EP97402502 | 1997-10-22 | ||
| PCT/GB1998/003117 WO1999020611A1 (en) | 1997-10-22 | 1998-10-19 | Imidazole derivatives and their use as farnesyl protein transferase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE205195T1 true ATE205195T1 (de) | 2001-09-15 |
Family
ID=26147905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98947694T ATE205195T1 (de) | 1997-10-22 | 1998-10-19 | Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US6342765B1 (de) |
| EP (1) | EP1025088B1 (de) |
| JP (1) | JP2001524455A (de) |
| AT (1) | ATE205195T1 (de) |
| AU (1) | AU9453098A (de) |
| DE (1) | DE69801590T2 (de) |
| DK (1) | DK1025088T3 (de) |
| ES (1) | ES2163295T3 (de) |
| PT (1) | PT1025088E (de) |
| WO (1) | WO1999020611A1 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000034437A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| WO2000034239A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| JP2002533476A (ja) | 1998-12-23 | 2002-10-08 | アストラゼネカ アクチボラグ | 化学化合物 |
| WO2001014314A1 (en) * | 1999-08-20 | 2001-03-01 | Nippon Kayaku Kabushiki Kaisha | Benzene derivatives having aromatic substituents and processes for the preparation thereof |
| GB9930317D0 (en) | 1999-12-22 | 2000-02-09 | Zeneca Ltd | Novel compounds |
| US6271418B1 (en) | 2000-02-22 | 2001-08-07 | Nippon Kayaku Co., Ltd. | Process for preparing (hetero) aromatic substituted benzene derivatives |
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| WO2004022097A1 (en) * | 2002-09-05 | 2004-03-18 | Medimmune, Inc. | Methods of preventing or treating cell malignancies by administering cd2 antagonists |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| AU2004229501B2 (en) | 2003-04-11 | 2011-08-18 | Medimmune, Llc | Recombinant IL-9 antibodies and uses thereof |
| US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
| EP2272566A3 (de) | 2003-08-18 | 2013-01-02 | MedImmune, LLC | Humanisierung von antikörpern |
| CA2585717A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| CA2602035C (en) | 2005-03-18 | 2015-06-16 | Medimmune, Inc. | Framework-shuffling of antibodies |
| KR20080025174A (ko) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
| KR101346902B1 (ko) | 2005-07-09 | 2014-01-02 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체 |
| AU2007290570C1 (en) | 2006-08-28 | 2013-08-15 | Kyowa Kirin Co., Ltd. | Antagonistic human LIGHT-specific human monoclonal antibodies |
| CA2682292A1 (en) | 2007-03-30 | 2008-10-09 | Medimmune, Llc | Aqueous formulation comprising an anti-human interferon alpha antibody |
| US8633297B2 (en) | 2007-10-31 | 2014-01-21 | Medimmune, Llc | Protein scaffolds |
| US9540443B2 (en) | 2011-01-26 | 2017-01-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
| NZ630363A (en) | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
| CA2887129A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
| SG11201509982UA (de) | 2013-06-06 | 2016-04-28 | Igenica Biotherapeutics Inc | |
| AU2014332442B2 (en) | 2013-08-26 | 2019-12-19 | Biontech Research And Development, Inc. | Nucleic acids encoding human antibodies to Sialyl-Lewis |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9856324B2 (en) | 2014-06-04 | 2018-01-02 | MabVax Therapeutics, Inc. | Human monoclonal antibodies to ganglioside GD2 |
| JP6800853B2 (ja) | 2014-12-11 | 2020-12-16 | ピエール、ファーブル、メディカマン | 抗ｃ１０ｏｒｆ５４抗体およびその使用 |
| KR20250005465A (ko) | 2015-03-03 | 2025-01-09 | 키맵 리미티드 | 항체, 용도 및 방법 |
| EP3383908A1 (de) | 2015-12-02 | 2018-10-10 | Stsciences, Inc. | Spezifische antikörper gegen glykosylierten btla (b- und t-lymphozyt-attenuator) |
| EP3383911B1 (de) | 2015-12-02 | 2021-01-20 | STCube & Co. Inc. | Antikörper und moleküle die immunspezifisch an btn1a1 binden und therapeutische verwendungen davon |
| EP3534947A1 (de) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren |
| CN111051346A (zh) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
| KR20200015602A (ko) | 2017-05-31 | 2020-02-12 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 |
| KR20200026209A (ko) | 2017-06-06 | 2020-03-10 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법 |
| WO2019073069A1 (en) | 2017-10-13 | 2019-04-18 | Boehringer Ingelheim International Gmbh | HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN) |
| CN112740043A (zh) | 2018-07-20 | 2021-04-30 | 皮埃尔法布雷医药公司 | Vista受体 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5944308B2 (ja) | 1976-03-23 | 1984-10-29 | 武田薬品工業株式会社 | ペプタイド |
| US4221803A (en) * | 1979-05-09 | 1980-09-09 | Recordati, S.A. | Substituted dibenzyl ethers and pharmaceutical compositions containing said ethers for the treatment of infections |
| FI803127A7 (fi) | 1979-10-03 | 1981-04-04 | Glaxo Group Ltd | Heterosyklisiä yhdisteitä. |
| US4518607A (en) * | 1983-07-18 | 1985-05-21 | Syntex (U.S.A.) Inc. | Male oral contraceptive N-alkylimidazole derivatives, compositions, and method of use therefor |
| US5298655A (en) | 1991-09-27 | 1994-03-29 | Merck & Co., Inc. | Farnesyl pyrophosphate analogs |
| US5238922A (en) | 1991-09-30 | 1993-08-24 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
| US5340828A (en) | 1991-09-30 | 1994-08-23 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
| US5352705A (en) | 1992-06-26 | 1994-10-04 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
| US5326773A (en) | 1992-10-29 | 1994-07-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| HUT77406A (hu) | 1994-03-15 | 1998-04-28 | Eisai Co., Ltd., | 1-(4-Amino-5-tio-pent-2-en)-il oldalláncot tartalmazó peptidomimetikumok és az ezeket tartalmazó gyógyszerkészítmények |
| CA2155448A1 (en) | 1994-08-11 | 1996-02-12 | Katerina Leftheris | Inhibitors of farnesyl protein transferase |
| US5478934A (en) | 1994-11-23 | 1995-12-26 | Yuan; Jun | Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands |
| WO1996030015A1 (en) * | 1995-03-29 | 1996-10-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5534537A (en) * | 1995-03-29 | 1996-07-09 | Merck & Co., Inc. | Prodrugs of inhibitors of farnesyl-protein transferase |
| US5710171A (en) | 1995-05-24 | 1998-01-20 | Merck & Co., Inc. | Bisphenyl inhibitors of farnesyl-protein transferase |
| GB9515975D0 (en) | 1995-08-04 | 1995-10-04 | Zeneca Ltd | Chemical compounds |
| EP0873123B1 (de) | 1995-11-06 | 2003-04-09 | University Of Pittsburgh | Inhibitoren der protein-isoprenyl-transferase |
| WO1998032741A1 (en) | 1997-01-29 | 1998-07-30 | Zeneca Limited | Inhibitors of farnesyl protein transferase |
-
1998
- 1998-10-19 AT AT98947694T patent/ATE205195T1/de not_active IP Right Cessation
- 1998-10-19 EP EP98947694A patent/EP1025088B1/de not_active Expired - Lifetime
- 1998-10-19 ES ES98947694T patent/ES2163295T3/es not_active Expired - Lifetime
- 1998-10-19 AU AU94530/98A patent/AU9453098A/en not_active Abandoned
- 1998-10-19 PT PT80103281T patent/PT1025088E/pt unknown
- 1998-10-19 JP JP2000516953A patent/JP2001524455A/ja not_active Withdrawn
- 1998-10-19 DE DE69801590T patent/DE69801590T2/de not_active Expired - Fee Related
- 1998-10-19 WO PCT/GB1998/003117 patent/WO1999020611A1/en not_active Ceased
- 1998-10-19 DK DK98947694T patent/DK1025088T3/da active
- 1998-10-19 US US09/509,210 patent/US6342765B1/en not_active Expired - Fee Related
-
2001
- 2001-09-20 US US09/956,005 patent/US20020058665A1/en not_active Abandoned
- 2001-09-20 US US09/955,994 patent/US20020052376A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1025088A1 (de) | 2000-08-09 |
| WO1999020611A1 (en) | 1999-04-29 |
| DE69801590D1 (de) | 2001-10-11 |
| DK1025088T3 (da) | 2001-11-12 |
| US20020058665A1 (en) | 2002-05-16 |
| US6342765B1 (en) | 2002-01-29 |
| ES2163295T3 (es) | 2002-01-16 |
| DE69801590T2 (de) | 2002-07-11 |
| JP2001524455A (ja) | 2001-12-04 |
| AU9453098A (en) | 1999-05-10 |
| EP1025088B1 (de) | 2001-09-05 |
| US20020052376A1 (en) | 2002-05-02 |
| PT1025088E (pt) | 2002-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69801590D1 (de) | Imidazolderivate und ihre verwendung als farnesylproteintransferase inhibitoren | |
| BR0113448A (pt) | Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase | |
| MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
| BR0014133A (pt) | Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
| BR0010520A (pt) | Novos compostos farmaceuticamente ativos | |
| BRPI9608082B8 (pt) | derivado de quinazolina, sal de cloridreto do mesmo, e, composição farmacêutica | |
| EP1259487B8 (de) | 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren | |
| AP1609A (en) | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation. | |
| NO913750D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater. | |
| BRPI0418074B8 (pt) | derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos | |
| AR102722A2 (es) | Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit | |
| DE69615674D1 (de) | Cyclobutan-derivate als inhibitoren der squalen-synthase und der protein farnesyltransferase | |
| YU87990A (sh) | Postupak za dobijanje novih bis-(1h-indol-3-il)-maleinimid derivata | |
| EA200501516A1 (ru) | Производные 2,3,6-тризамещённого-4-пиримидона | |
| BRPI0409110A (pt) | derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer | |
| BR0207846A (pt) | Derivados heterocìclicos para o tratamento de câncer e outras doenças proliferativas | |
| DK0565377T3 (da) | Terapeutiske midler til behandling af Parkinsons sygdom | |
| ATE291018T1 (de) | Pyrazol verbindungen und ihre verwendung | |
| MA23639A1 (fr) | Derives pyrrocarbazole, leur preparation, les compositions pharmaceutiques les contenant, leur utilisation dans le traitement des tumeurs malignes. | |
| DE69533194D1 (de) | PYRAZOLO(3,4-g)CHINOXALINE ALS PDGF-REZEPTOR PROTEIN TYROSIN-KINASE INHIBITOREN | |
| DE60004340D1 (de) | Substituierte 1,4-dihydroindeno[1,2-c]pyrazole als inhibitoren von tyrosinkinase | |
| KR890001957A (ko) | N-아미노부틸-n-페닐아릴아미드 유도체, 그의 제법 및 치료에의 응용 | |
| ATE185560T1 (de) | Von pyridin und imidazol abgeleitete mittel für kardiovaskuläre krankheiten | |
| DE69512208D1 (de) | Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren | |
| ATE374366T1 (de) | Aminophenoxyacetamid derivate und diese enthaltende pharmazeutische zusammensetzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REN | Ceased due to non-payment of the annual fee |